Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids

F. Shojaee Aliabadi, Badrelin H. Ali, M. F. Landoni, P. Lees

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel in a two period cross-over study. After intravenous (i.v.) administration at a dose rate of 1.25 mg/kg, the pharmacokinetics of danofloxacin indicated a high volume of distribution (V darea=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) and half-life of 5.37 h. After intramuscular (i.m.) dosing absorption was complete (F=114.5) and rapid (T (1/2)abs=0.12 h) and terminal half-life was 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) and non-inflamed (transudate) tissue cage fluids and was cleared slowly from these fluids, elimination half-life being at least twice that for serum for both exudate and transudate after both i.v. and i.m. dosing. The antibacterial actions of danofloxacin against the camel pathogen Escherichia coli 0157-H7 were determined by measurement of minimum inhibitory concentration (MIC) in vitro (single measurement) and ex vivo measurements of bacterial count at nine times between one and 48 h after i.m. dosing in each of the fluids, serum, exudate, and transudate. Using in vitro MIC data and in vivo pharmacokinetic parameters, the surrogate markers of antimicrobial activity, C max/MIC, AUC/MIC and T>MIC, were determined for all three fluids. The ex vivo serum AUC 24h/MIC data were integrated with reduction in bacterial count to provide values producing a bacteriostatic action (no change in bacterial count), inhibition of bacterial count by 50%, reduction in bacterial count by 99.9% (bactericidal action) and elimination of bacteria. Mean AUC 24h/MIC values were 17.20, 20.07, 21.24, and 68.37 h, respectively. To describe the latter, the introduction of a new term to supplement MIC and minimum bactericidal concentration (MBC) is proposed, namely minimum elimination concentration (MEC). A novel means of designing antimicrobial drug dosage schedules for evaluation in clinical trials is proposed, using ex vivo AUC 24h/MIC values for bactericidal activity and elimination of bacteria together with MIC 90 data for camel pathogens.

Original languageEnglish
Pages (from-to)104-118
Number of pages15
JournalVeterinary Journal
Volume165
Issue number2
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Culture Diffusion Chambers
danofloxacin
Camelus
Microbial Sensitivity Tests
camels
minimum inhibitory concentration
pharmacokinetics
cages
Pharmacokinetics
Bacterial Load
Serum
plate count
Exudates and Transudates
Area Under Curve
half life
Half-Life
anti-infective agents
fluids
tissues
Bacteria

Keywords

  • Camel
  • Danofloxacin
  • Exudate
  • Pharmacokinetics
  • PK-PD modelling
  • Serum
  • Transudate

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids. / Shojaee Aliabadi, F.; Ali, Badrelin H.; Landoni, M. F.; Lees, P.

In: Veterinary Journal, Vol. 165, No. 2, 03.2003, p. 104-118.

Research output: Contribution to journalArticle

Shojaee Aliabadi, F. ; Ali, Badrelin H. ; Landoni, M. F. ; Lees, P. / Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids. In: Veterinary Journal. 2003 ; Vol. 165, No. 2. pp. 104-118.
@article{8875ab71561b40689ae45388844e26d1,
title = "Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids",
abstract = "The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel in a two period cross-over study. After intravenous (i.v.) administration at a dose rate of 1.25 mg/kg, the pharmacokinetics of danofloxacin indicated a high volume of distribution (V darea=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) and half-life of 5.37 h. After intramuscular (i.m.) dosing absorption was complete (F=114.5) and rapid (T (1/2)abs=0.12 h) and terminal half-life was 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) and non-inflamed (transudate) tissue cage fluids and was cleared slowly from these fluids, elimination half-life being at least twice that for serum for both exudate and transudate after both i.v. and i.m. dosing. The antibacterial actions of danofloxacin against the camel pathogen Escherichia coli 0157-H7 were determined by measurement of minimum inhibitory concentration (MIC) in vitro (single measurement) and ex vivo measurements of bacterial count at nine times between one and 48 h after i.m. dosing in each of the fluids, serum, exudate, and transudate. Using in vitro MIC data and in vivo pharmacokinetic parameters, the surrogate markers of antimicrobial activity, C max/MIC, AUC/MIC and T>MIC, were determined for all three fluids. The ex vivo serum AUC 24h/MIC data were integrated with reduction in bacterial count to provide values producing a bacteriostatic action (no change in bacterial count), inhibition of bacterial count by 50{\%}, reduction in bacterial count by 99.9{\%} (bactericidal action) and elimination of bacteria. Mean AUC 24h/MIC values were 17.20, 20.07, 21.24, and 68.37 h, respectively. To describe the latter, the introduction of a new term to supplement MIC and minimum bactericidal concentration (MBC) is proposed, namely minimum elimination concentration (MEC). A novel means of designing antimicrobial drug dosage schedules for evaluation in clinical trials is proposed, using ex vivo AUC 24h/MIC values for bactericidal activity and elimination of bacteria together with MIC 90 data for camel pathogens.",
keywords = "Camel, Danofloxacin, Exudate, Pharmacokinetics, PK-PD modelling, Serum, Transudate",
author = "{Shojaee Aliabadi}, F. and Ali, {Badrelin H.} and Landoni, {M. F.} and P. Lees",
year = "2003",
month = "3",
doi = "10.1016/S1090-0233(02)00258-7",
language = "English",
volume = "165",
pages = "104--118",
journal = "Veterinary Journal",
issn = "1090-0233",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids

AU - Shojaee Aliabadi, F.

AU - Ali, Badrelin H.

AU - Landoni, M. F.

AU - Lees, P.

PY - 2003/3

Y1 - 2003/3

N2 - The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel in a two period cross-over study. After intravenous (i.v.) administration at a dose rate of 1.25 mg/kg, the pharmacokinetics of danofloxacin indicated a high volume of distribution (V darea=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) and half-life of 5.37 h. After intramuscular (i.m.) dosing absorption was complete (F=114.5) and rapid (T (1/2)abs=0.12 h) and terminal half-life was 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) and non-inflamed (transudate) tissue cage fluids and was cleared slowly from these fluids, elimination half-life being at least twice that for serum for both exudate and transudate after both i.v. and i.m. dosing. The antibacterial actions of danofloxacin against the camel pathogen Escherichia coli 0157-H7 were determined by measurement of minimum inhibitory concentration (MIC) in vitro (single measurement) and ex vivo measurements of bacterial count at nine times between one and 48 h after i.m. dosing in each of the fluids, serum, exudate, and transudate. Using in vitro MIC data and in vivo pharmacokinetic parameters, the surrogate markers of antimicrobial activity, C max/MIC, AUC/MIC and T>MIC, were determined for all three fluids. The ex vivo serum AUC 24h/MIC data were integrated with reduction in bacterial count to provide values producing a bacteriostatic action (no change in bacterial count), inhibition of bacterial count by 50%, reduction in bacterial count by 99.9% (bactericidal action) and elimination of bacteria. Mean AUC 24h/MIC values were 17.20, 20.07, 21.24, and 68.37 h, respectively. To describe the latter, the introduction of a new term to supplement MIC and minimum bactericidal concentration (MBC) is proposed, namely minimum elimination concentration (MEC). A novel means of designing antimicrobial drug dosage schedules for evaluation in clinical trials is proposed, using ex vivo AUC 24h/MIC values for bactericidal activity and elimination of bacteria together with MIC 90 data for camel pathogens.

AB - The pharmacokinetics and pharmacodynamics of danofloxacin were studied in the camel in a two period cross-over study. After intravenous (i.v.) administration at a dose rate of 1.25 mg/kg, the pharmacokinetics of danofloxacin indicated a high volume of distribution (V darea=3.43 L/kg), relatively rapid clearance (0.44 L/kg/h) and half-life of 5.37 h. After intramuscular (i.m.) dosing absorption was complete (F=114.5) and rapid (T (1/2)abs=0.12 h) and terminal half-life was 5.71 h. Danofloxacin penetrated fairly slowly into both inflamed (exudate) and non-inflamed (transudate) tissue cage fluids and was cleared slowly from these fluids, elimination half-life being at least twice that for serum for both exudate and transudate after both i.v. and i.m. dosing. The antibacterial actions of danofloxacin against the camel pathogen Escherichia coli 0157-H7 were determined by measurement of minimum inhibitory concentration (MIC) in vitro (single measurement) and ex vivo measurements of bacterial count at nine times between one and 48 h after i.m. dosing in each of the fluids, serum, exudate, and transudate. Using in vitro MIC data and in vivo pharmacokinetic parameters, the surrogate markers of antimicrobial activity, C max/MIC, AUC/MIC and T>MIC, were determined for all three fluids. The ex vivo serum AUC 24h/MIC data were integrated with reduction in bacterial count to provide values producing a bacteriostatic action (no change in bacterial count), inhibition of bacterial count by 50%, reduction in bacterial count by 99.9% (bactericidal action) and elimination of bacteria. Mean AUC 24h/MIC values were 17.20, 20.07, 21.24, and 68.37 h, respectively. To describe the latter, the introduction of a new term to supplement MIC and minimum bactericidal concentration (MBC) is proposed, namely minimum elimination concentration (MEC). A novel means of designing antimicrobial drug dosage schedules for evaluation in clinical trials is proposed, using ex vivo AUC 24h/MIC values for bactericidal activity and elimination of bacteria together with MIC 90 data for camel pathogens.

KW - Camel

KW - Danofloxacin

KW - Exudate

KW - Pharmacokinetics

KW - PK-PD modelling

KW - Serum

KW - Transudate

UR - http://www.scopus.com/inward/record.url?scp=0347706219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347706219&partnerID=8YFLogxK

U2 - 10.1016/S1090-0233(02)00258-7

DO - 10.1016/S1090-0233(02)00258-7

M3 - Article

C2 - 12573598

AN - SCOPUS:0347706219

VL - 165

SP - 104

EP - 118

JO - Veterinary Journal

JF - Veterinary Journal

SN - 1090-0233

IS - 2

ER -